US Edition
FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response
Summary by sharecafe.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Extends Review Timeline for Neurizon’s NUZ-001 Clinical Hold Response
Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, has announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline for its Clinical Hold Complete Response (CHCR) to the Investigational New Drug (IND) application for NUZ-001. NUZ-001 is the company’s lead investigational therapy targeting amyotrophic lateral scleros…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
